120 related articles for article (PubMed ID: 18589556)
1. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers.
Kirkov V; Dimitrova V; Siebert-Weigel M; Wolf-Pflugmann M; Koytchev R; Richter W; Bronn A; Arsova S; Kromminga A
Arzneimittelforschung; 2008; 58(5):220-4. PubMed ID: 18589556
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st Communication: A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers.
Kirkov V; Dimitrova V; Siebert-Weigel M; Wolf-Pflugmann M; Koytchev R; Richter W; Bronn A; Arsova S; Kromminga A
Arzneimittelforschung; 2008; 58(5):215-9. PubMed ID: 18589555
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.
Togawa A; Tanaka T; Nagashima S; Keta H; Kobayashi Y; Nishikawa Y; Yanai M; Tanaka H
Br J Clin Pharmacol; 2004 Sep; 58(3):269-76. PubMed ID: 15327586
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers.
Kim TE; Kim KP; Kim BH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2010 Oct; 32(11):1968-76. PubMed ID: 21095491
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.
Cheung W; Minton N; Gunawardena K
Eur J Clin Pharmacol; 2001 Aug; 57(5):411-8. PubMed ID: 11599659
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.
Lerner G; Kale AS; Warady BA; Jabs K; Bunchman TE; Heatherington A; Olson K; Messer-Mann L; Maroni BJ
Pediatr Nephrol; 2002 Nov; 17(11):933-7. PubMed ID: 12432437
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
Milutinović S; Plavljanić E; Trkulja V
Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration.
Fishbane S; Pannier A; Liogier X; Jordan P; Dougherty FC; Reigner B
J Clin Pharmacol; 2007 Nov; 47(11):1390-7. PubMed ID: 17962427
[TBL] [Abstract][Full Text] [Related]
14. A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.
Berthoux F; Ryckelynck JP; Rouanet S; Gelu-Mantoulet S; Montestruc F; Mouchel P; Choukroun G;
Clin Nephrol; 2008 Jul; 70(1):33-40. PubMed ID: 18793546
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
Lissy M; Ode M; Roth K
Drugs R D; 2011; 11(1):61-75. PubMed ID: 21410296
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.
Halstenson CE; Macres M; Katz SA; Schnieders JR; Watanabe M; Sobota JT; Abraham PA
Clin Pharmacol Ther; 1991 Dec; 50(6):702-12. PubMed ID: 1752115
[TBL] [Abstract][Full Text] [Related]
17. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
Vercaigne LM; Collins DM; Penner SB
J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial.
Sörgel F; Thyroff-Friesinger U; Vetter A; Vens-Cappell B; Kinzig M
BMC Clin Pharmacol; 2009 May; 9():10. PubMed ID: 19463151
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.
Arroliga AC; Guntupalli KK; Beaver JS; Langholff W; Marino K; Kelly K
Crit Care Med; 2009 Apr; 37(4):1299-307. PubMed ID: 19242343
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study.
Oh M; Yoon J; Cho DY
Clin Drug Investig; 2015 Oct; 35(10):659-64. PubMed ID: 26369656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
